Enhanced Contrast Imaging for Screening of Early Pancreatic Cancer

增强对比成像筛查早期胰腺癌

• 批准号: 7537923
• 负责人: NICUSOR IFTIMIA
• 金额: $ 15.2万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-11 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7537923
• 关键词: Abdomen; Acinar Cell; Address; Age; Animal Model; Animals; Area; Award; Binding; Biological; Blood Circulation; Cancer Etiology; Cancer cell line; Cancerous; Capital; Catheters; Cell Line; Cells; Clinical; Clinical Research; Collaborations; Computer software; Condition; Connective Tissue; Data; Data Set; Depth; Detection; Development; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Disease; Ductal; Ductal Epithelial Cell; Ductal Epithelium; Dyes; Early Diagnosis; Effectiveness; Encapsulated; Endocrine; Endoscopy; Engineering; Epidermal Growth Factor Receptor; Epithelial; Equipment; Evaluation; Feasibility Studies; Flour; Fluorescence; Fluorescent Dyes; Frequencies; Funding; Gastrointestinal tract structure; Gelatin; Genes; Goals; Gold; Government; Growth; Hand; Hepatic Duct; Histology; Human; Image; Indocyanine Green; Intravenous; Invasive; Label; Lasers; Lateral; Lesion; Light; Local Therapy; Localized; Location; Lung; Lymphoid Tissue; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of pancreas; Measurement; Medical Surveillance; Methods; Modality; Modeling; Molecular Probes; Morbidity - disease rate; Morphology; Nanotechnology; Normal Cell; Nude Mice; Numbers; Optical Coherence Tomography; Optics; Organ; Organ Size; Outcome; Pancreas; Pancreatic Ductal Adenocarcinoma; Pancreatic duct; Patients; Peptides; Personal Satisfaction; Persons; Peutz-Jeghers Syndrome; Pharmaceutical Preparations; Phase; Probability; Process; Property; Public Health; Purpose; Qualifying; Reporting; Research; Research Personnel; Resolution; Scanning; Screening for cancer; Screening procedure; Sensitivity and Specificity; Signal Transduction; Solutions; Source; Specificity; Specimen; Speed; Staging; Structure; Surface; Survival Rate; Symptoms; System; Techniques; Technology; Testing; Therapeutic; Three-Dimensional Image; Three-Dimensional Imaging; Time; Tissues; Topical application; Translating; Ultrasonography; United States; United States Food and Drug Administration; United States National Institutes of Health; Universities; Work; base; bile duct; cancer cell; cancer diagnosis; cancer site; chronic pancreatitis; data acquisition; design; fluorescence imaging; fluorophore; imaging probe; improved; in vivo; instrument; instrumentation; millimeter; mortality; mouse model; nanoparticle; neoplastic; neoplastic cell; optical imaging; pancreatic neoplasm; particle; physical science; programs; size; targeted delivery; tomography; tool; tumor; tumor xenograft

DESCRIPTION (provided by applicant): This proposal addresses a real need for an improved technology for early detection and rapid screening of ductal pancreatic cancer. Very recent advances in nanotechnology and high resolution optical coherence tomography (OCT) imaging have led to the development of new investigative tools capable of probing biological tissues at the cellular level. These tools can be used to localize abnormal neoplastic cells and expedite the cancer screening process. Physical Sciences Inc. (PSI), in collaboration with Northeastern University (NEU), proposes to develop a technology that could be used for screening of early stage epithelial cancerous lesions of the pancreatic duct. Endoscopically guided high-resolution OCT imaging, combined with fluorescence imaging, will be used to localize abnormal lesions within the tissue. Gold-coated gelatin-based particles, loaded with a fluorophore and functionalized to recognize the epidermal growth factor receptor (EGFR), will be topically or intravenously delivered to the body to target cancer cells, indicate cancer location, and enhance the contrast of OCT imaging. In Phase I, this technology will be tested on various pancreatic cancer cell lines in cultures and in an orthotropic mouse model of human pancreatic cancer. The Phase I results and observations will be used to improve this technology in a Phase II program. A pilot in vivo study on a large number of animals will be performed in Phase II to test the effectiveness of this technology for early stage ductal pancreatic cancer screening. PUBLIC HEALTH RELEVANCE: The proposed research could substantially improve cancer screening and surveillance, allowing for detection at an early stage when it is treatable and more easily curable. It is well established that earlier cancer diagnosis results in improved clinical outcomes, decreased morbidity, and reduced mortality from disease.

描述（由申请人提供）：该提案解决了对用于胰腺导管癌的早期检测和快速筛查的改进技术的真实的需求。纳米技术和高分辨率光学相干断层扫描（OCT）成像的最新进展导致了能够在细胞水平上探测生物组织的新研究工具的开发。这些工具可用于定位异常肿瘤细胞并加快癌症筛查过程。物理科学公司(PSI)与东北大学（NEU）合作，提出开发一种可用于筛查早期胰腺导管上皮癌病变的技术。将使用内窥镜引导的高分辨率OCT成像结合荧光成像定位组织内的异常病变。载有荧光团并具有识别表皮生长因子受体（EGFR）功能的金涂层明胶颗粒将被局部或静脉内递送到体内，以靶向癌细胞、指示癌症位置并增强OCT成像的对比度。在第一阶段，这项技术将在培养的各种胰腺癌细胞系和人类胰腺癌的正交各向异性小鼠模型中进行测试。第一阶段的结果和观察结果将用于在第二阶段计划中改进这项技术。将在II期对大量动物进行初步体内研究，以测试该技术用于早期胰腺导管癌筛查的有效性。公共卫生相关性：这项拟议中的研究可以大大改善癌症筛查和监测，允许在可治疗且更容易治愈的早期阶段进行检测。众所周知，早期癌症诊断可改善临床结局，降低发病率和疾病死亡率。